盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用  

Role of discoidin domain receptor 1 in the regulation of malignant tumor progression and therapy

作　　者：李潭 梁新华[1] Li Tan;Liang Xinhua(State Key Laboratory of Oral Diseases&National Clinical Research Center for Oral Diseases&Dept.of Oral Surgery,West China Hospital of Stomatology,Sichuan University,Chengdu 610041,China)

机构地区：[1]口腔疾病研究国家重点实验室、国家口腔疾病临床医学研究中心、四川大学华西口腔医院口腔外科门诊,成都610041

出　　处：《国际口腔医学杂志》2023年第2期230-236,共7页International Journal of Stomatology

基　　金：国家自然科学基金(82073000)。

摘　　要：盘状蛋白结构域受体1 (DDR1)是特殊类型的跨膜受体酪氨酸激酶,在口腔鳞状细胞癌等多种肿瘤中异常表达,并能调控肿瘤进展相关的分子通路。DDR1可参与多种生物学过程,如细胞增殖、分化、迁移、侵袭、休眠和凋亡,还与肿瘤的上皮间充质转化、免疫排斥、代谢重编程和化疗药物耐药密切相关。部分DDR1抑制剂已在临床研究中显示出抗癌功效。本文回顾了DDR1在肿瘤进展中和DDR1抑制剂在肿瘤治疗中的作用,以期为恶性肿瘤的靶向治疗提供新思路。Discoidin domain receptor 1(DDR1) is a special type of transmembrane receptor tyrosine kinase that is aberrantly expressed in various tumors, including oral squamous cell carcinoma, and can regulate molecular pathways related to tumor progression. DDR1 is involved in a variety of biological processes, such as cell proliferation, differentiation, migration, invasion, dormancy, and apoptosis, and is also closely related to tumor epithelial-mesenchymal transition, immune rejection, metabolic reprogramming, and chemotherapeutic drug resistance. Some DDR1 inhibitors have shown anticancer efficacy in clinical studies. This article reviews the roles of DDR1 in tumor progression and DDR1 inhibitors in tumor therapy to provide new ideas for the targeted therapy of malignant tumors.

关 键 词：盘状蛋白结构域受体1 口腔鳞状细胞癌 恶性肿瘤 抑制剂 靶向治疗 

分 类 号：Q257[生物学—细胞生物学]